| ID Source | ID |
|---|---|
| PubMed CID | 9953271 |
| SCHEMBL ID | 170065 |
| MeSH ID | M0258598 |
| Synonym |
|---|
| ad5061 |
| ad 5061 |
| ad-5061 |
| ad7057 |
| gtpl2663 |
| 5-({4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione |
| ad 7057 |
| 5-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| ad-7057 |
| SCHEMBL170065 |
| 5-{4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl}-2,4-thiazolidinedione |
| GUTCYOKMCPFRGH-UHFFFAOYSA-N |
| bm-131246 |
| CS-6704 |
| HY-101758 |
| Q27074311 |
| 103787-97-9 |
| AKOS040732615 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | IC50 (µMol) | 0.0140 | 0.0050 | 1.2051 | 10.0000 | AID223558 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | Ki | 0.0043 | 0.0000 | 0.3790 | 5.6000 | AID157275 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | IC50 (µMol) | 4.0860 | 0.0005 | 0.8269 | 6.3100 | AID223553 |
| ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | IC50 (µMol) | 0.0140 | 0.0043 | 1.0703 | 8.2000 | AID223558 |
| ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | IC50 (µMol) | 0.0140 | 0.0043 | 1.3686 | 8.2000 | AID223558 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | EC50 (µMol) | 0.0056 | 0.0000 | 0.9922 | 10.0000 | AID157124; AID223555 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | EC50 (µMol) | 0.7710 | 0.0006 | 1.6074 | 10.0000 | AID223550 |
| ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | EC50 (µMol) | 0.7710 | 0.0219 | 1.1257 | 8.8000 | AID223550 |
| ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | EC50 (µMol) | 0.7710 | 0.0219 | 0.9708 | 8.8000 | AID223550 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID157124 | Activation of peroxisome proliferator activated receptor gamma measured by induction of 50% of maximum alkaline phosphatase activity, transfection assay in CV-1 cells | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25 | N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. |
| AID127973 | Effective dose to reduce 25% of glucose levels in blood | 1992 | Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14 | Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. |
| AID223550 | Binding affinity at human PPAR alpha | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13 | Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. |
| AID157275 | In vitro binding to peroxisome proliferator activated receptor gamma (PPAR gamma) using [3H]-BRL 49653 as radioligand in scintillation proximity assay (SPA) | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25 | N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. |
| AID223555 | Binding affinity at human PPAR gamma | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13 | Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. |
| AID223557 | Transcriptional activation in CV- cells expressing hPPARgamma | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13 | Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. |
| AID136474 | Maximum reduction in plasma triglyceride levels in KKA mice at a dosage of 0.005% in diet | 1992 | Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14 | Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. |
| AID223553 | Binding affinity towards human peroxidase proliferator activated receptor alpha (hPPARalpha) | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13 | Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. |
| AID223552 | Transcriptional activation in CV-1 cells expressing hPPARalpha | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13 | Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. |
| AID127974 | Effective dose to reduce 25% of triglyceride levels in plasma | 1992 | Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14 | Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. |
| AID136473 | Maximum reduction in plasma triglyceride levels in KKA mice at a dosage of 0.001% in diet | 1992 | Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14 | Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. |
| AID136469 | Maximum reduction in blood glucose levels in KKA mice at a dosage of 0.001% in diet | 1992 | Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14 | Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. |
| AID136470 | Maximum reduction in blood glucose levels in KKA mice at a dosage of 0.005% in diet | 1992 | Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14 | Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. |
| AID111617 | Antihyperglycemic activity was determined by measuring percent decrease in plasma glucose at 1 mg/kg/day | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents. |
| AID3423 | Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells | 1998 | Journal of medicinal chemistry, May-21, Volume: 41, Issue:11 | Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents. |
| AID111619 | Antihyperglycemic activity was determined by measuring percent decrease in plasma glucose at 5 mg/kg/day | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents. |
| AID223558 | Binding affinity at human peroxidase proliferator activated receptor gamma (hPPARgamma) | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13 | Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. |
| AID1346800 | Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors) | 2000 | Biochemical and biophysical research communications, Nov-30, Volume: 278, Issue:3 | Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. |
| AID1346733 | Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors) | 2004 | European journal of pharmacology, Jul-08, Volume: 495, Issue:1 | A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. |
| AID1346800 | Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors) | 2004 | European journal of pharmacology, Jul-08, Volume: 495, Issue:1 | A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. |
| AID1346733 | Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors) | 2000 | Biochemical and biophysical research communications, Nov-30, Volume: 278, Issue:3 | Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. |
| AID493017 | Wombat Data for BeliefDocking | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13 | Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.15) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||